https://www.biospace.com/curefaktor-pharmaceuticals-llc-demonstrates-novel-focal-adhesion-kinase-fak-inhibitor-disrupts-fak-vegfr3-interaction-and-inhibits-pancreatic-tumor
CureFAKtor Pharmaceuticals. LLC Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor Disrupts...
focal adhesion kinasefak inhibitorpharmaceuticalsllcdemonstrates
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2015-00546&r=1
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with...
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
fak inhibitorvismodegibcapivasertib
https://www.southampton.ac.uk/research/projects/a-al-shamkhani-verastem-inc-combinations-of-immunostimulatory-antibodies-a-fak
A Al-Shamkhani - Verastem Inc - Combinations of immunostimulatory antibodies and a FAK inhibitor...
A Al-Shamkhani - Verastem Inc - Combinations of immunostimulatory antibodies and a FAK inhibitor for the treatment of cancer.
https://www.biospace.com/live-from-asco-2024-ascentage-pharma-releases-updated-data-of-fak-alk-ros1-inhibitor-apg-2449-in-patients-with-nsclc
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in...
Jul 17, 2024 - Ascentage Pharma announced that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor, in patients with...